
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.
A recap of the FDA submissions and regulatory decisions in urology from July 2025.
Welcome to Urology Times’® monthly FDA update! In July, notable advancements were made in the development of a combination regimen for metastatic prostate cancer, an emerging agent in non–muscle invasive bladder cancer (NMIBC), a medication for hypoactive sexual desire disorder (HSDD), and more.





